Art

J-GLOBAL ID：201602207124613656   Reference number：16A0105928

A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial

経口血糖降下薬単剤投与下の2型糖尿病日本人患者におけるデュラグルチドの1年間の安全性研究:非盲検非ランダム化第三相試験

Author (6)： EMOTO Masanori (Dep. of Metabolism, Endocrinology & Molecular Medicine, Osaka City Univ. Graduate School of Medicine, Osaka ...) ,  TERAUCHI Yasuo (Dep. of Endocrinology & Metabolism, Yokohama City Univ. School of Medicine, Yokohama, 236-0004, JPN) ,  OZEKI Akichika (Eli Lilly Japan K.K., Kobe, 651-0086, JPN) ,  OURA Tomonori (Eli Lilly Japan K.K., Kobe, 651-0086, JPN) ,  TAKEUCHI Masakazu (Eli Lilly Japan K.K., Kobe, 651-0086, JPN) ,  IMAOKA Takeshi (Eli Lilly Japan K.K., Kobe, 651-0086, JPN)
Material： Endocrine Journal  (Endocr J)
Volume： 62  Issue： 12  Page： 1101-1114 (J-STAGE)  Publication year： 2015 
JST Material Number： F0625A  ISSN： 0918-8959  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *GLP-1 receptor agonist ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A0105928&from=J-GLOBAL&jstjournalNo=F0625A") }}

JST classification (1)： Treatment for metabolic diseases,nutritional diseases.  (GD05030F)

Substance index (1)： 2,4-Thiazolidinedione

Reference (33)：

• 1. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, et al. (2002) The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 Suppl 3:S434-S442.
• 2. Gutzwiller JP, Degen L, Heuss L, Beglinger C (2004) Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 82:17-19.
• 3. Mudaliar S, Henry RR (2009) Incretin therapies: effects beyond glycemic control. Am J Med 122:S25-S36.
• 4. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, et al. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13:394-407.
• 5. Lorenz M, Evers A, Wagner M (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 23:4011-4018.

Terms in the title (11)： 経口血糖降下薬 ,  単剤投与 ,  2型糖尿病 ,  日本人 ,  患者 ,  デュラグルチド ,  安全性 ,  研究 ,  盲 ,  ランダム化 ,  第三相試験